The high prevalence of catheter-associated urinary tract infections (CAUTIs) is causing significant concern in healthcare systems. Antibacterial urinary catheters have been developed to prevent CAUTIs in clinical application. In this work, a copper sulfide nanorod (CuS NR)-embedded urinary catheter (CuS/UC) was designed as an antibacterial urinary catheter with photothermal sterilization. The CuS NRs with low cytotoxicity were synthesized via the hydrothermal method. The CuS NRs were embedded into urinary catheters at different weight percentages. The CuS/UC exhibited homogenous surface roughness, low wettability, hydrophobicity, and low adhesiveness, promoting minimal interaction with bacteria and healthy cells. Under near-infrared (NIR) laser irradiation, the 0.8 weight percentage of CuS NRs in the urinary catheter (0.8CuS/UC) reached a temperature of 67.4 °C, demonstrating its photothermal antibacterial activity and suitability for catheter sterilization. Agar plate test verified that CuS/UCs exhibited a superior photothermal antibacterial activity against both Gram-negative Escherichia coli (E. coli) and Gram-positive Streptococcus aureus (S. aureus). Moreover, the 0.8CuS/UC exhibited excellent biocompatibility and anti-cell adhesion properties. The 0.8CuS/UC with photothermal performance, excellent biocompatibility, and anti-cell adhesion properties demonstrated its potential as a photothermal antibacterial catheter for clinical applications.
The high prevalence of catheter-associated urinary tract infections (CAUTIs) has become a significant concern in the healthcare system, prompting the development of antibacterial urinary catheters to effectively prevent these infections in clinical settings. In this work, metallic phase and semiconducting phase molybdenum disulfide (MoS2) embedded polydimethylsiloxane (PDMS) were developed as antibacterial urinary catheters with photothermal sterilization. The metallic phase MoS2 (1T-MoS2) was synthesized using a facile hydrothermal method, and an annealing process transformed it into the semiconducting phase (2H-MoS2). The optical and structural characterizations confirmed the successful preparations of 1T-MoS2 nanosheets (1T-MoS2 NSs) and 2H-MoS2 NSs. The increase in the contents of 1T-MoS2 NSs and 2H-MoS2 NSs in PDMS resulted in enhanced photothermal conversion, a slight decrease in the water contact angle, and no significant changes in the mechanical properties of the samples. The bacterial growth curves demonstrated the remarkable ability of phase-dependent 1T- and 2H-MoS2 NSs-embedded PDMS urinary catheters to inhibit the growth of E. coli and S. aureus with near-infrared (NIR) laser irradiation. In the agar plate test, exposing PDMS with 0.3% 1T-MoS2 or 2H-MoS2 to NIR for 10 min demonstrated excellent antibacterial effects, completely eradicating E. coli and eliminating over 99.9% of S. aureus. The SEM image results highlighted the significant photothermal antibacterial effect of 1T-MoS2 PDMS and 2H-MoS2 PDMS urinary catheters, effectively damaging and eradicating both E. coli and S. aureus. The 1T-MoS2 PDMS and 2H-MoS2 PDMS urinary catheters, with excellent photothermal effects, good hydrophobicity, and superior mechanical properties, demonstrated their potential as photothermal antibacterial catheters for clinical applications.
Background: Myocardial infarction (MI) triggers excessive oxidative stress, inflammatory activation, and maladaptive fibrosis, leading to adverse ventricular remodeling and heart failure. Therapeutic strategies capable of simultaneously modulating oxidative, inflammatory, and angiogenic pathways remain limited. This study investigates the cardioprotective effects of a novel Multifunctional Peptide (MFP) engineered to possess antioxidant, anti-inflammatory, pro-angiogenic, and endothelial-regenerative activities in a rat model of MI. Methods: Adult male Sprague–Dawley rats underwent left anterior descending (LAD) coronary artery ligation to induce MI, followed by intramyocardial administration of MFP into peri-infarct myocardium. Cardiac remodeling and function were assessed via echocardiography and histopathology at 4 weeks post-MI. Macrophage phenotypes, fibrosis, angiogenesis, and apoptosis were evaluated using immunohistochemistry. In vitro studies examined MFP-mediated cytoprotection in H9C2 cardiomyocytes under oxidative stress and its effects on macrophage polarization in RAW 264.7 cells. RNA-sequencing was performed to identify transcriptomic signatures regulated by MFP. Results: MFP treatment significantly improved left ventricular systolic function and attenuated post-MI structural deterioration. Histological analyses showed reduced cardiomyocyte apoptosis, diminished interstitial fibrosis, and markedly increased capillary density. MFP decreased pro-inflammatory macrophage infiltration while promoting reparative M2 macrophage polarization in vivo. In vitro, MFP protected cardiomyocytes against oxidative damage and enhanced M2-polarizing signaling in macrophages. Transcriptomic profiling revealed downregulation of genes associated with necrosis, inflammation, and adverse remodeling, and upregulation of pathways related to tissue repair, angiogenesis, and immune modulation. Conclusion: MFP confers robust cardioprotection after MI by coordinating the suppression of oxidative stress and inflammation with the enhancement of angiogenic and reparative pathways. These findings support MFP as a promising therapeutic candidate for limiting infarct injury and improving myocardial repair.